Tag: drug
GlaxoSmithKline jumps into myeloma with ‘homemade’ anti-BCMA drug Blenrep
Back in 2015, GlaxoSmithKline traded away its marketed cancer assets and began building its oncology pipeline “pretty aggressively,” as Axel Hoos, the company’s SVP...
FDA raises concerns over ocular toxicity from GSK’s potential first-in-class myeloma...
A document posted online ahead of a Food and Drug Administration expert panel meeting to determine whether or not to recommend accelerated approval for...
Remdesivir stockpiling could help push COVID drug into profitable territory for...
Ever since the FDA last month cleared Gilead’s remdesivir for emergency use to treat COVID-19, investors have been wondering if the drug could possibly...
Are metformin recalls just the start? Valisure CEO calls for independent...
With another quality scandal on its hands with diabetes drug metformin, the FDA could be looking at another global recall of a commonly used med....
Amgen data on drug with ‘undruggable’ target at ASCO gets muted...
Amgen’s booth at the 2019 ASCO conference in Chicago
A leading contender in the race to develop drugs that target a type of commonly expressed...
FDA’s Hahn: No sign China has affected U.S. drug supply during...
With pharmaceutical supply chains under immense pressure due to the novel coronavirus, China's role as a global ingredient producer has come under scrutiny. Despite...
Incyte plans Phase III trial of blood cancer drug as potential...
A paper published last month suggested that one of the reasons behind severe Covid-19 disease might be cytokine storm, a kind of out-of-control immune...
Intercept’s hotly anticipated NASH drug has to wait for its FDA...
Intercept Pharmaceuticals and its closely watched nonalcoholic steatohepatitis (NASH) candidate have hit another snag, this one courtesy of the coronavirus pandemic.
The FDA has put...
Teva forecasts worse-than-expected ‘trough year’ as generics hammer MS drug Copaxone
Shares of Teva fell nearly 12% in pre-market trading to $16.80 after the company’s executives conceded during the fourth-quarter earnings report that 2019 would...
Biotech that bought GSK’s ‘bubble boy’ drug to build stem cell...
Another cell manufacturing facility will be built in the U.S., this one by a transatlantic biotech in which GlaxoSmithKline owns a sizable share.
The U.K.-based...
